Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000776)

(Analysis AN001226)

Metabolite	Structure	F1	F2	F3	F4
FFA(24:3)	ME214636	0.17	2.53	0.14	1.16
lysoPE 22:2; [M-H]-@2.86	ME214823	0.12	2.47	0.06	1.36
lysoPE 24:4; [M-H]-@2.55	ME214827	0.30	2.83	0.19	0.67
PG 40:5; [M-H]-@5.64	ME214773	0.51	2.77	0.24	0.49
PG 42:8; [M-H]-@5.10	ME214781	0.56	2.90	0.10	0.44
PG 44:8; [M-H]-@5.57	ME214786	0.62	2.81	0.09	0.48
PG 44:9; [M-H]-@5.38	ME214787	0.65	2.62	0.31	0.41
PG 38:4; [M-H]-@5.34	ME214767	0.56	2.49	0.37	0.57
PG 38:5; [M-H]-@5.03	ME214769	0.62	2.42	0.31	0.66
FFA(22:3)	ME214632	0.31	2.64	0.12	0.93
PG 40:6; [M-H]-@5.34	ME214774	0.48	2.56	0.22	0.74
PG 42:9; [M-H]-@4.78	ME214782	0.47	2.45	0.18	0.90
PG 44:10; [M-H]-@5.08	ME214783	0.56	2.41	0.18	0.85
PE 40:4; [M-H]-@7.37	ME214739	1.75	1.26	0.58	0.40
PS 40:4; [M-H]-@6.32	ME214814	1.98	1.13	0.61	0.28
PS 38:6; [M-H]-@5.14	ME214811	0.76	0.29	2.30	0.65
PS 40:5; [M-H]-@5.97	ME214815	0.58	0.32	2.34	0.76
PS 40:6; [M-H]-@5.76	ME214816	0.62	0.30	2.32	0.77
PS 38:5; [M-H]-@5.44	ME214810	0.79	0.29	1.99	0.93
PI 34:1; [M-H]-@5.58	ME214788	0.59	0.48	1.92	1.01
PS 40:7; [M-H]-@5.26	ME214817	0.65	0.45	1.92	0.98
PE 38:7; [M-H]-@5.58	ME214730	0.61	0.24	1.36	1.79
PA 38:5; [M-H]-@5.34	ME214642	0.19	0.62	1.67	1.52
PC 36:5; [M-Ac-H]-@5.78	ME214671	0.31	0.43	1.68	1.59
PE 36:6; [M-H]-@5.44	ME214719	0.25	0.33	1.69	1.74
PI 40:6; [M-H]-@5.70	ME214800	0.21	0.77	1.25	1.76
PC 34:5; [M-Ac-H]-@5.21	ME214661	0.24	0.49	1.36	1.91
plasmenyl-PE 30:0; [M-H]-@6.47	ME214829	0.33	0.63	1.25	1.78
PI 38:6; [M-H]-@4.95	ME214797	0.31	0.55	1.37	1.77
plasmenyl-PE 42:6; [M-H]-@7.75	ME214853	0.31	0.60	1.40	1.69
PC 38:7; [M-Ac-H]-@5.56	ME214679	0.44	0.65	1.29	1.62
PI 38:5; [M-H]-@5.32	ME214796	0.50	0.62	1.33	1.55
CL 68:1; [M-2H](2-)@7.35	ME214604	0.41	0.56	1.46	1.56
plasmenyl-PE 38:6; [M-H]-@6.54	ME214843	0.48	0.61	1.43	1.48
PE 35:2; [M-H]-@6.66	ME214714	0.62	0.67	1.11	1.59
PE 37:5; [M-H]-@6.02	ME214724	0.53	0.57	1.21	1.69
PG 42:11; [M-H]-@4.04	ME214778	0.11	0.42	0.82	2.65
PG 44:12; [M-H]-@4.37	ME214785	0.07	0.27	0.88	2.77
plasmenyl-PE 36:5; [M-H]-@6.19	ME214838	0.11	0.19	1.38	2.32
PC 42:11; [M-Ac-H]-@5.36	ME214692	0.20	0.62	1.08	2.10
PE 37:6; [M-H]-@5.93	ME214725	0.33	0.48	1.02	2.17
lysoPE 26:0; [M-H]-@6.06	ME214828	0.11	1.35	0.22	2.33
FFA(22:2)	ME214631	0.20	2.19	0.15	1.46
lysoPE 22:1; [M-H]-@3.46	ME214822	0.11	2.09	0.10	1.70
lysoPE 24:1; [M-H]-@4.37	ME214826	0.09	2.01	0.12	1.77
PE 38:0; [M-H]-@8.43	ME214726	0.25	1.45	0.48	1.81
PG 40:7; [M-H]-@4.95	ME214775	0.38	1.56	0.38	1.68
PG 42:10; [M-H]-@4.49	ME214777	0.44	1.55	0.33	1.68
FFA(22:0)	ME214629	0.37	1.40	0.38	1.85
FFA(24:1)	ME214634	0.36	1.51	0.34	1.78
PE 40:0; [M-H]-@8.89	ME214735	0.33	1.54	0.27	1.86
plasmenyl-PE 33:0; [M-H]-@6.93	ME214830	0.27	1.72	0.48	1.53
PC 46:4; [M-Ac-H]-@9.30	ME214704	0.36	1.79	0.37	1.48
PG 40:8; [M-H]-@4.51	ME214776	0.42	1.72	0.44	1.42
Arachidonic acid	ME214603	0.43	1.74	0.37	1.46
PE 30:0; [M-H]-@6.05	ME214705	0.39	1.72	0.40	1.48
FFA(20:1)	ME214627	0.30	1.69	0.27	1.74
lysoPE 21:0; [M-H]-@3.89	ME214821	0.18	1.71	0.30	1.81
lysoPE 18:0; [M-H]-@2.38	ME214819	0.19	1.77	0.26	1.78
lysoPE 20:0; [M-H]-@3.36	ME214820	0.18	1.80	0.24	1.79
FFA(20:2)	ME214628	0.21	1.99	0.21	1.59
lysoPE 14:0; [M-H]-@1.05	ME214818	0.32	1.84	0.29	1.55
PG 38:6; [M-H]-@4.68	ME214770	0.30	1.84	0.25	1.60
FFA(22:1)	ME214630	0.23	1.86	0.21	1.70
FFA(24:2)	ME214635	0.23	1.89	0.24	1.64
CL 74:9; [M-2H](2-)@8.92	ME214616	0.96	0.80	1.39	0.84
PS 38:3; [M-H]-@6.10	ME214808	0.75	0.97	1.52	0.76
PC 38:5; [M-Ac-H]-@6.46	ME214677	0.77	1.09	1.09	1.06
PC 40:5; [M-Ac-H]-@7.30	ME214685	0.78	1.18	0.99	1.05
PC 37:4; [M-Ac-H]-@6.63	ME214672	0.62	1.11	1.15	1.12
PS 38:1; [M-H]-@6.92	ME214806	0.70	1.06	1.16	1.08
PE 39:1; [M-H]-@8.27	ME214731	0.70	1.06	1.00	1.24
plasmenyl-PE 38:2; [M-H]-@7.85	ME214840	0.65	1.07	1.09	1.19
PS 39:4; [M-H]-@6.04	ME214812	0.87	0.93	1.21	0.99
PE 38:5; [M-H]-@6.52	ME214729	0.83	0.89	1.14	1.13
PE 40:5; [M-H]-@7.07	ME214740	0.84	0.86	1.22	1.09
CL 78:9; [M-2H](2-)@6.52	ME214621	0.85	0.89	1.03	1.23
PE 37:4; [M-H]-@6.65	ME214723	0.86	0.99	0.97	1.17
PE 40:8; [M-H]-@5.93	ME214742	0.79	0.82	1.09	1.29
PS 34:1; [M-H]-@5.73	ME214801	0.77	0.82	1.10	1.31
CL 72:7; [M-2H](2-)@9.04	ME214610	0.70	0.82	1.23	1.25
plasmenyl-PE 40:5; [M-H]-@7.32	ME214849	0.75	0.86	1.19	1.20
PE 39:6; [M-H]-@6.46	ME214734	0.92	0.60	1.28	1.20
CL 72:8; [M-2H](2-)@8.87	ME214611	0.64	0.72	1.55	1.09
PS 36:2; [M-H]-@5.82	ME214804	0.77	0.61	1.65	0.97
plasmenyl-PE 40:6; [M-H]-@7.20	ME214850	0.63	0.75	1.27	1.35
PC 38:6; [M-Ac-H]-@6.06	ME214678	0.57	0.73	1.34	1.36
PS 35:1; [M-H]-@6.03	ME214802	0.61	0.75	1.36	1.28
PC 40:6; [M-Ac-H]-@6.72	ME214686	0.46	0.71	1.58	1.25
PE 40:6; [M-H]-@6.89	ME214741	0.62	0.60	1.50	1.28
PC 42:3; [M-Ac-H]-@8.47	ME214694	0.49	1.53	0.57	1.41
PC 44:5; [M-Ac-H]-@8.26	ME214702	0.47	1.56	0.49	1.48
PG 32:0; [M-H]-@5.66	ME214756	0.42	1.40	0.61	1.58
plasmenyl-PE 36:0; [M-H]-@8.22	ME214834	0.41	1.42	0.67	1.51
PC 30:0; [M-Ac-H]-@6.02	ME214647	0.48	1.45	0.58	1.49
PC 44:3; [M-Ac-H]-@9.17	ME214701	0.46	1.44	0.64	1.46
CL 68:2; [M-2H](2-)@9.54	ME214605	0.51	1.37	0.65	1.47
PC 29:0; [M-Ac-H]-@5.65	ME214646	0.52	1.43	0.64	1.41
FFA(20:0)	ME214626	0.44	1.34	0.53	1.68
PE 44:3; [M-H]-@8.81	ME214753	0.47	1.29	0.58	1.66
PC 42:2; [M-Ac-H]-@8.87	ME214693	0.42	1.23	0.66	1.69
PE 42:2; [M-H]-@8.51	ME214746	0.40	1.22	0.59	1.79
PC 40:0; [M-Ac-H]-@9.32	ME214681	0.29	1.35	0.70	1.66
plasmenyl-PE 38:1; [M-H]-@8.27	ME214839	0.44	1.32	0.80	1.45
PE 40:1; [M-H]-@8.46	ME214736	0.48	1.26	0.68	1.59
PA 36:4; [M-H]-@5.07	ME214640	0.38	1.29	0.75	1.57
PI 38:3; [M-H]-@6.01	ME214794	0.43	1.23	0.76	1.59
PE 37:3; [M-H]-@6.92	ME214722	0.43	1.17	1.15	1.25
PI 36:1; [M-H]-@6.09	ME214790	0.54	1.08	1.07	1.32
PC 32:4; [M-Ac-H]-@4.95	ME214653	0.47	1.11	1.08	1.34
PC 42:6; [M-Ac-H]-@7.25	ME214697	0.45	1.09	1.11	1.36
PS 39:6; [M-H]-@5.44	ME214813	0.33	1.23	0.95	1.48
PC 42:1; [M-Ac-H]-@9.35	ME214691	0.45	1.10	0.79	1.67
plasmenyl-PE 36:1; [M-H]-@7.72	ME214835	0.46	1.07	0.76	1.72
PC 35:1; [M-Ac-H]-@7.19	ME214663	0.42	1.07	0.90	1.61
PG 32:1; [M-H]-@5.15	ME214757	0.35	1.07	0.92	1.67
plasmenyl-PE 36:2; [M-H]-@7.29	ME214836	0.64	0.86	1.01	1.49
PE 37:1; [M-H]-@7.68	ME214720	0.50	0.89	1.00	1.61
PG 33:1; [M-H]-@5.43	ME214759	0.54	0.93	0.92	1.61
PE 34:0; [M-H]-@6.67	ME214710	0.65	0.94	0.89	1.51
PE 36:2; [M-H]-@6.95	ME214717	0.69	0.98	0.87	1.47
CL 74:3; [M-2H](2-)@6.85	ME214612	0.67	1.01	0.81	1.52
PE 34:1; [M-H]-@6.84	ME214711	0.63	0.98	0.81	1.59
PC 41:1; [M-Ac-H]-@9.04	ME214690	0.58	1.13	0.97	1.32
PC 34:3; [M-Ac-H]-@5.89	ME214659	0.61	1.06	0.94	1.39
PC 38:0; [M-Ac-H]-@8.66	ME214673	0.66	1.03	0.94	1.37
PI 34:2; [M-H]-@5.14	ME214789	0.56	0.99	0.92	1.53
PC 33:0; [M-Ac-H]-@7.00	ME214654	0.52	1.07	0.87	1.54
PC 34:2; [M-Ac-H]-@6.32	ME214658	0.54	1.05	0.88	1.52
PE 41:1; [M-H]-@8.73	ME214743	0.53	1.12	0.90	1.45
PC 40:7; [M-Ac-H]-@6.27	ME214687	0.50	1.01	1.01	1.47
PA 34:1; [M-H]-@5.61	ME214638	0.55	1.03	0.97	1.44
plasmenyl-PE 34:0; [M-H]-@7.64	ME214831	0.50	1.08	0.97	1.44
PE 35:0; [M-H]-@7.60	ME214712	0.69	1.27	0.57	1.47
PE 39:3; [M-H]-@7.50	ME214732	0.75	1.11	0.75	1.40
PE 40:2; [M-H]-@8.00	ME214737	0.75	1.20	0.69	1.37
FFA(16:0)	ME214622	0.69	1.14	0.82	1.35
CL 72:6; [M-2H](2-)@9.25	ME214609	0.66	1.07	0.83	1.44
PC 34:1; [M-Ac-H]-@6.78	ME214657	0.65	1.12	0.83	1.40
PI 36:2; [M-H]-@5.79	ME214791	0.56	1.19	0.77	1.47
PC 32:1; [M-Ac-H]-@6.14	ME214652	0.58	1.18	0.83	1.41
PC 38:1; [M-Ac-H]-@8.16	ME214674	0.61	1.23	0.79	1.38
PE 38:2; [M-H]-@7.50	ME214728	0.64	1.18	0.77	1.41
CL 78:3; [M-2H](2-)@7.48	ME214620	0.65	1.09	0.70	1.56
PC 33:1; [M-Ac-H]-@6.51	ME214655	0.59	1.05	0.78	1.58
PC 35:3; [M-Ac-H]-@6.21	ME214665	0.58	1.12	0.80	1.49
PE 38:1; [M-H]-@7.97	ME214727	0.61	1.09	0.78	1.52
PC 38:2; [M-Ac-H]-@7.59	ME214675	0.59	1.13	0.73	1.56
PC 40:1; [M-Ac-H]-@8.74	ME214682	0.55	1.14	0.78	1.54
FFA(18:1)	ME214624	0.59	1.26	0.63	1.53
PI 36:3; [M-H]-@5.28	ME214792	0.56	1.20	0.65	1.59
CL 70:5; [M-2H](2-)@9.19	ME214607	0.60	1.06	0.66	1.67
CL 70:4; [M-2H](2-)@9.37	ME214606	0.49	1.18	0.70	1.63
FFA(18:2)	ME214625	0.54	1.14	0.66	1.66
PC 43:4; [M-Ac-H]-@8.53	ME214699	0.60	1.65	0.44	1.32
PE 46:4; [M-H]-@8.92	ME214755	0.50	1.65	0.57	1.27
CL 74:6; [M-2H](2-)@9.49	ME214613	0.72	1.53	0.57	1.17
PE 44:4; [M-H]-@8.59	ME214754	0.61	1.47	0.65	1.27
PE 43:4; [M-H]-@8.35	ME214750	0.69	1.35	0.88	1.08
plasmenyl-PE 40:2; [M-H]-@8.31	ME214845	0.58	1.39	0.88	1.16
PC 27:0; [M-Ac-H]-@4.97	ME214644	0.69	1.43	0.92	0.95
PC 35:4; [M-Ac-H]-@6.02	ME214666	0.78	1.31	0.95	0.97
plasmenyl-PE 38:3; [M-H]-@7.57	ME214841	0.81	1.53	0.68	0.98
PG 36:2; [M-H]-@5.93	ME214762	0.82	1.37	0.80	1.01
PG 33:0; [M-H]-@5.93	ME214758	0.88	1.33	0.71	1.07
plasmenyl-PE 36:4; [M-H]-@6.60	ME214837	0.89	1.30	0.79	1.02
PC 39:1; [M-Ac-H]-@8.43	ME214680	0.60	1.36	0.76	1.27
PC 30:1; [M-Ac-H]-@5.50	ME214648	0.53	1.34	0.79	1.33
PC 40:8; [M-Ac-H]-@5.87	ME214688	0.53	1.33	0.80	1.34
CL 72:5; [M-2H](2-)@9.43	ME214608	0.84	1.30	0.70	1.16
PE 42:3; [M-H]-@8.14	ME214747	0.86	1.23	0.70	1.22
PC 36:0; [M-Ac-H]-@7.97	ME214667	0.76	1.32	0.67	1.26
PC 40:3; [M-Ac-H]-@7.78	ME214683	0.75	1.32	0.60	1.33
PE 36:0; [M-H]-@7.89	ME214716	0.67	1.18	0.88	1.27
PG 34:1; [M-H]-@5.72	ME214760	0.73	1.16	0.84	1.27
PC 30:2; [M-Ac-H]-@4.98	ME214649	0.62	1.24	0.89	1.25
PI 40:5; [M-H]-@5.88	ME214799	0.60	1.24	0.93	1.23
PI 36:4; [M-H]-@5.10	ME214793	0.66	1.31	0.83	1.19
PC 32:0; [M-Ac-H]-@6.71	ME214651	0.68	1.28	0.79	1.25
PC 36:3; [M-Ac-H]-@6.51	ME214669	0.68	1.24	0.85	1.24
FFA(18:0)	ME214623	0.78	1.12	0.87	1.24
PC 36:1; [M-Ac-H]-@7.49	ME214668	0.76	1.05	0.91	1.28
PE 36:3; [M-H]-@6.55	ME214718	0.80	1.03	0.89	1.28
CL 74:8; [M-2H](2-)@9.14	ME214615	0.87	1.13	0.87	1.13
plasmenyl-PE 42:5; [M-H]-@7.89	ME214852	0.74	1.20	0.91	1.15
PC 33:2; [M-Ac-H]-@6.06	ME214656	0.76	1.23	0.82	1.19
PE 35:4; [M-H]-@6.05	ME214715	0.80	1.19	0.81	1.20
PE 31:0; [M-H]-@6.43	ME214706	0.28	1.20	0.43	2.10
FFA(24:0)	ME214633	0.55	1.16	0.46	1.83
PG 38:7; [M-H]-@4.21	ME214771	0.49	0.82	0.72	1.97
plasmenyl-PE 34:1; [M-H]-@7.12	ME214832	0.42	0.98	0.70	1.89
PG 44:11; [M-H]-@4.73	ME214784	0.22	1.05	0.69	2.03
plasmenyl-PE 40:0; [M-H]-@9.15	ME214844	0.26	1.05	0.72	1.97
PE 43:1; [M-H]-@9.18	ME214749	0.38	0.98	0.60	2.04
PE 44:2; [M-H]-@8.95	ME214752	0.46	1.00	0.52	2.02
PC 44:2; [M-Ac-H]-@9.44	ME214700	0.44	1.13	0.57	1.86
PE 33:0; [M-H]-@7.07	ME214708	0.43	1.09	0.62	1.86
PE 32:1; [M-H]-@6.21	ME214707	0.40	1.07	0.59	1.94
PE 42:1; [M-H]-@8.91	ME214745	0.36	1.14	0.55	1.95
PE 44:1; [M-H]-@9.37	ME214751	0.33	1.09	0.57	2.01
PE 35:1; [M-H]-@7.14	ME214713	0.50	0.80	0.91	1.79
PC 31:1; [M-Ac-H]-@5.88	ME214650	0.39	0.86	0.95	1.80
PG 34:2; [M-H]-@5.30	ME214761	0.45	0.81	0.99	1.74
lysoPE 22:5; [M-H]-@1.44	ME214825	0.44	0.76	1.13	1.67
PC 34:6; [M-Ac-H]-@4.84	ME214662	0.35	0.90	1.15	1.61
PC 35:2; [M-Ac-H]-@6.65	ME214664	0.88	0.78	0.83	1.52
PE 33:2; [M-H]-@6.05	ME214709	0.73	0.73	0.84	1.69
PE 37:2; [M-H]-@7.25	ME214721	0.62	0.91	0.78	1.70
lysoPE 22:4; [M-H]-@1.73	ME214824	1.13	1.92	0.41	0.53
PG 36:4; [M-H]-@4.88	ME214765	0.43	1.62	1.08	0.86
PG 42:6; [M-H]-@5.83	ME214779	0.39	1.49	1.13	0.99
plasmenyl-PE 34:3; [M-H]-@6.35	ME214833	0.31	1.94	0.58	1.17
PG 42:7; [M-H]-@5.38	ME214780	0.64	2.19	0.45	0.72
PC 44:8; [M-Ac-H]-@6.89	ME214703	0.40	2.09	0.60	0.90
PC 26:0; [M-Ac-H]-@4.55	ME214643	0.60	1.90	0.61	0.89
PG 38:2; [M-H]-@6.01	ME214766	0.57	2.03	0.58	0.83
PG 36:3; [M-H]-@5.22	ME214763	0.52	1.70	0.79	0.99
PC 28:0; [M-Ac-H]-@5.29	ME214645	0.66	1.62	0.75	0.97
PC 42:5; [M-Ac-H]-@7.62	ME214696	0.69	1.67	0.71	0.93
PC 34:4; [M-Ac-H]-@5.62	ME214660	0.66	1.85	0.77	0.72
PG 40:4; [M-H]-@6.02	ME214772	0.61	1.87	0.82	0.71
PI 40:4; [M-H]-@6.11	ME214798	0.79	1.78	0.67	0.75
plasmenyl-PE 40:3; [M-H]-@8.07	ME214846	0.78	1.69	0.68	0.85
plasmenyl-PE 42:4; [M-H]-@8.17	ME214851	0.74	1.90	0.62	0.74
PC 42:4; [M-Ac-H]-@8.13	ME214695	0.76	1.87	0.53	0.84
PC 42:8; [M-Ac-H]-@6.40	ME214698	0.81	1.92	0.47	0.80
CL 76:10; [M-2H](2-)@9.05	ME214617	1.36	0.89	1.02	0.73
PS 36:4; [M-H]-@5.22	ME214805	1.26	0.71	1.35	0.68
PS 38:4; [M-H]-@5.88	ME214809	1.34	0.87	1.28	0.51
PA 38:4; [M-H]-@5.75	ME214641	1.30	1.39	0.66	0.65
PC 38:4; [M-Ac-H]-@6.86	ME214676	1.27	1.42	0.76	0.54
CL 76:8; [M-2H](2-)@9.39	ME214618	1.26	1.55	0.43	0.76
PC 40:4; [M-Ac-H]-@7.41	ME214684	1.47	1.41	0.48	0.65
PA 34:0; [M-H]-@6.09	ME214637	0.92	1.40	1.08	0.60
PG 36:4; [M-H]-@5.35	ME214764	0.79	1.42	1.06	0.72
PS 36:1; [M-H]-@6.31	ME214803	0.94	1.07	1.11	0.88
PC 40:9; [M-Ac-H]-@5.49	ME214689	0.96	1.19	1.12	0.73
PE 41:4; [M-H]-@7.58	ME214744	1.00	1.23	1.05	0.72
PI 38:4; [M-H]-@5.74	ME214795	0.98	1.19	0.99	0.84
PS 38:2; [M-H]-@6.39	ME214807	0.90	1.25	0.97	0.88
CL 74:7; [M-2H](2-)@6.07	ME214614	1.05	1.22	0.68	1.05
PA 36:1; [M-H]-@6.19	ME214639	0.99	1.15	0.85	1.01
PE 39:4; [M-H]-@7.19	ME214733	1.06	1.06	0.92	0.96
PC 36:4; [M-Ac-H]-@6.19	ME214670	1.19	1.29	0.83	0.69
PG 38:4; [M-H]-@5.97	ME214768	1.14	1.18	0.83	0.84
CL 76:9; [M-2H](2-)@9.21	ME214619	1.12	1.45	0.54	0.89
plasmenyl-PE 38:4; [M-H]-@7.23	ME214842	1.03	1.43	0.74	0.80
plasmenyl-PE 40:4; [M-H]-@7.66	ME214848	1.06	1.46	0.71	0.77
plasmenyl-PE 40:4; [M-H]-@7.88	ME214847	1.06	1.46	0.71	0.77
PE 40:3; [M-H]-@7.64	ME214738	1.06	1.29	0.76	0.90
PE 42:4; [M-H]-@8.04	ME214748	1.10	1.34	0.72	0.84

Factors:

F1	Fish Oil:NO \| Tumor:NO
F2	Fish Oil:NO \| Tumor:YES
F3	Fish Oil:YES \| Tumor:NO
F4	Fish Oil:YES \| Tumor:YES

Data matrix